Leaving the hospital after radiopharmaceutical cancer treatment can mean taking home pages of complex instructions that patients are expected to follow. LifeNuclear, a University of Alabama at Birmingham (UAB) startup, aims to simplify that experience by turning radiation safety guidance into an easy-to-follow digital resource.
Radiopharmaceutical therapy is an advanced cancer treatment that delivers targeted radiation directly to cancer cells throughout the body. As treatment becomes more widely used, patients often leave with lengthy written instructions that can be difficult to understand and follow.
Remo George, Ph.D., UAB Assistant Professor in the Nuclear Medicine and Molecular Imaging Sciences Program, founded LifeNuclear to simplify that experience. The company’s first product, TheraGuide, is a digital platform designed to transform those complex paper instructions into clear, accessible guidance for patients and caregivers. 
“LifeNuclear is a digital health company focused on improving patient guidance, education, and safety for people receiving radiopharmaceutical therapies,” George said. “Our first product, TheraGuide, is being developed to help patients and caregivers better understand and follow radiation safety instructions after treatment.”
The platform includes treatment-specific guidance, easy-to-understand educational content, interactive checklists, multilingual support, and personalized timelines that deliver the right information at the appropriate time throughout each stage of treatment, rather than simply presenting patients with static educational materials.
“Our goal is to make complex radiation safety instructions easier to understand, easier to follow, and easier to reference whenever questions arise at home,” George said.
The idea for the company grew from a conversation with a colleague who described how difficult it could be for patients to understand the written instructions they received after treatment.
“That conversation resonated with me because I have always believed that important medical information should be understandable to everyone,” George said. “I also know from personal experience that lengthy written instructions can be overwhelming. That experience motivated me to create a simpler, more patient-friendly approach.”
Today, LifeNuclear has reached several key milestones, including executing a licensing agreement with UAB, developing the TheraGuide prototype and successfully deploying it through Apple’s TestFlight platform for beta evaluation. The company has also assembled a multidisciplinary leadership, including interim CEO Gae Stoops, MSN, RN, CPHQ, who leads business operations and commercialization efforts, migration to an Apple Organization Developer account, and development of the TheraGuide prototype.
George said one of the biggest challenges has been navigating the legal, regulatory, and organizational steps required to bring a healthcare product to market.
“Rather than taking shortcuts, we have focused on building a strong foundation through careful planning, collaboration, and guidance from UAB’s Harbert Institute and many supportive colleagues,” George said.
Looking ahead, LifeNuclear plans to continue refining TheraGuide with feedback from clinical partners while preparing for pilot evaluations and future collaborations.
“Our hope is that patients will feel more confident, informed, and supported throughout their treatment,” George said. “As radiopharmaceutical therapies continue to expand, we believe digital guidance tools can become an important part of helping patients safely manage their care outside the hospital.”
To learn more about LifeNuclear, visit https://www.lifenuclear.com/.
-- July 20, 2026